生物技术发明专利审查中的风险评价制度  

The Risk Assessment System of Patent Examining of Biotechnological Invention

作　　者：王子灿[1,2,3] 

机构地区：[1]重庆大学法学 [2]华南理工大学法学院 [3]知识产权学院

出　　处：《知识产权》2015年第2期69-73,共5页Intellectual Property

基　　金：重庆市博士后科研项目特别资助(项目编号:Xm2014074)

摘　　要：我国《专利法》除第5条用以预防科学技术危害外,还应当增设生物技术风险评价制度以控制生物技术风险。在专利申请的实质性审查阶段增设生物技术风险评价制度,在广泛的公众参与下,结合生物技术发明人的技术风险自我评价,由特定的生物技术风险评价机构对生物技术发明的生态风险、社会风险以及人体健康风险进行风险评价,最终由专利审查机构针对风险评价的结论对高风险生物技术不授予专利授权,从而阻滞高风险生物技术的产业化发展,实现专利法控制生物技术风险的基本功能。In addition to art. 5 of China Patent Law which regulates science and technological hazards, it is necessary to establish the risk assessment system of biotechnological technology in patent examining procedure, in order to control the risk of biotechnological technology. It is advised that the patent examining division should decide whether a biotechnological patent can be granted or not after considering the risk assessment results of health risk assessment, environmental risk assessment and social risk assessment made by particular risk assessment agencies, in order to prevent the industrial development of the high risk biotechnological technology and realize the basic function ofoatent law to control the biotechnological technologw risk.

关 键 词：生物技术发明 专利审查 风险评价 

分 类 号：D923.42[政治法律—民商法学]